Addendum

Nivolumab (NSCLC) - Addendum to Commission A20-118

Status
Status: Commission completed
Project no.
A21-57
Last updated

Report documents

  1. Addendum

    Nivolumab (NSCLC) - Addendum to Commission A20-118

    published on
    Document type
    PDF document, 1 MB, EN, not accessible

Dossier assessment

Indication:

First-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitizing EGFR mutation or ALK translocation

Result of dossier assessment:

Patients with PD-L1 expression (TPS) ≥ 50%: added benefit not proven.

Patients with PD-L1 expression (TPS) < 50% and brain metastases: indication of an added benefit; extent “considerable”.

Patients with PD-L1 expression (TPS) < 50% without brain metastases: indication of an added benefit; extent “minor”.

Additional information

Federal Joint Committee (G-BA)

2021.06.04 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A21-57
Commission
Commission awarded on 29.04.2021 by the Federal Joint Committee (GBA).
Report type
Addendum
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

Connected Projects

  1. Dossier assessment

    Nivolumab (non-small cell lung cancer, combination with ipilimumab) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-118
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form